BiOMViS
BiOMViS Srl is a biotech company dedicated to the development of prophylactic and immunotherapeutic interventions for infectious diseases and cancer. The company leverages a proprietary vaccine platform based on bacterial Outer Membrane Vesicles (OMVs), utilizing innovative genetic engineering and production processes to create safe, highly immunogenic vaccines. Their mission is to foster advancements in vaccine technology, with a focus on simplicity, efficiency, and safety, aiming to address unmet medical needs in infectious diseases and oncology.
Industries
Nr. of Employees
small (1-50)
BiOMViS
Patents
Method for the production of outer membrane vesicles and immunogenic compositions thereof
US-12551544-B2
View DetailsFhuD2 fusion proteins for the outer membrane vesicle (OMV) delivery of heterologous polypetides and immunogenic compositions thereof
US-12054521-B2
View DetailsImmunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
US-11066453-B2
View Details
Method for the production of outer membrane vesicles and immunogenic compositions thereof
US-12551544-B2
View DetailsFhuD2 fusion proteins for the outer membrane vesicle (OMV) delivery of heterologous polypetides and immunogenic compositions thereof
US-12054521-B2
View DetailsImmunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
US-11066453-B2
View DetailsProducts
OMV-based vaccine candidates (pipeline)
Pipeline of vaccine candidates using engineered bacterial OMVs as delivery and adjuvant platforms for prophylactic and immunotherapeutic applications in infectious diseases and cancer.
OMV-based vaccine candidates (pipeline)
Pipeline of vaccine candidates using engineered bacterial OMVs as delivery and adjuvant platforms for prophylactic and immunotherapeutic applications in infectious diseases and cancer.
Services
Design and preclinical development of vaccines based on bacterial outer membrane vesicles, including strain engineering, antigen expression, OMV production and formulation.
Establishment and use of in vitro and in vivo models to validate cancer antigen constructs and evaluate immune responses and safety biomarkers.
Characterization of OMVs and expressed antigens using microscopy, flow cytometry, proteomics, mass spectrometry and protein purification techniques available via on-site facilities.
Design and preclinical development of vaccines based on bacterial outer membrane vesicles, including strain engineering, antigen expression, OMV production and formulation.
Establishment and use of in vitro and in vivo models to validate cancer antigen constructs and evaluate immune responses and safety biomarkers.
Characterization of OMVs and expressed antigens using microscopy, flow cytometry, proteomics, mass spectrometry and protein purification techniques available via on-site facilities.
Expertise Areas
- OMV-based vaccine platform development
- Bacterial strain engineering for biologics
- Antigen design and lipidation for membrane targeting
- Preclinical immunogenicity and reactogenicity assessment
Key Technologies
- Outer membrane vesicles (OMVs)
- Bacterial strain engineering (gene deletions, LPS pathway modification)
- Lipidation-based antigen targeting
- Expression vector engineering